The performance of pharmaceutical companies in the third quarter is generally good, and Q4 can pay attention to these segments

【Pharmaceutical Network Market Analysis】Entering the disclosure period of the third quarterly report, the "report card" of pharmaceutical companies in the first three quarters of this year has surfaced one after another
.
As of 14:26 on October 20, 9 companies in the pharmaceutical and biological industry, including Poinsettia, Propharmaceutical, Kangyuan Pharmaceutical, Huatedyne, and Vanze, have disclosed their three quarterly results, and the overall performance is generally good
.
Pharmaceutical industry (Image source: Pharmaceutical Network) The performance of pharmaceutical companies in the third quarter is generally good Combing found that in addition to Poinsettia and Propharmaceutical, most pharmaceutical companies, including Kangyuan Pharmaceutical, Huatdyne, Wanze Co.
, Ltd.
, Chenxin Pharmaceutical, Guobang Pharmaceutical, Wantai Biotechnology, Shuoshi Biotechnology, etc.
, achieved year-on-year growth
in net profit attributable to the parent in the first three quarters of this year.
In the first three quarters of this year, the net profit attributable to the parent increased by 231.
91% to 3.
944 billion yuan, and at the same time, revenue also doubled, with a year-on-year increase of 140.
56%.

For the double increase in performance, Wantai Biologics said that it was due to the increase
in revenue from bivalent cervical cancer vaccines.
In addition, more than 40 pharmaceutical companies have released performance forecasts for the first three quarters, and more than eighty percent of companies are happy with their
performance.
Among them, Northeast Pharmaceutical, New Open Source, Cap Biologics, Rhein Biologics and many other companies are expected to double their performance in the first three quarters of this year, and Northeast Pharmaceutical expects the net profit attributable to the parent in the first three quarters to increase by more than 350% year-on-year, with an increase range of 351.
02% to 449.
07
%.
As for the reasons for the growth of performance, Northeast Pharmaceutical attributed the company's use of structural adjustment, technical research, process optimization, cost reduction and efficiency improvement, financial management level and other measures, while actively carrying out sales business, formulating differentiated marketing strategies, and achieving significant growth in
sales revenue 。 Affected by the bright performance of listed pharmaceutical companies in the first three quarters, the market pessimism gradually faded, coupled with the recent relatively moderate price reduction of centralized procurement, the introduction of biochemical detection reagents and electrophysiological centralized procurement rules, the resonance of new policies in the field of medical devices and other factors, the overall performance of the pharmaceutical and biological industry in the near future is better, since the beginning of October, as of October 19, the cumulative increase of the pharmaceutical biological index during the period reached 8.
64%.

Q4 can pay attention to these subdivisions The industry generally believes that the third quarterly report is of guiding significance for Q4, and we can pay attention to companies and sectors
whose performance continues to improve or exceed expectations in the third quarter.
From the perspective of pharmaceutical companies with outstanding performance in the third quarter, they are mainly concentrated in vaccines, medical devices, traditional Chinese medicine and other sectors
.
Among them, the future expectations of the vaccine industry have been relatively clear, including: HPV vaccines have a good competition pattern in the short term, and it is expected to achieve rapid volume with policy support; Rabies vaccine and influenza vaccine have a number of manufacturers, and have basically entered the stage of stock competition; Shingles vaccine has attracted high attention, and only one GSK product has been approved for marketing in the world, which is still a blue ocean market
.
However, the industry believes that the revenue and profit growth rate of the vaccine sector will be relatively slow down in 2022, and the overall trend reversal of the sector still needs to wait for the market sentiment to change
.
Not long ago, the national organization of orthopedic spine consumables successfully opened bidding, and the average price reduction of the selected products was 84%, and the overall reduction was relatively moderate
.
The industry believes that centralized procurement is conducive to promoting the replacement of domestic related enterprises, and at the same time, under the trend of new medical infrastructure, the medical device industry is expected to usher in a high prosperity
.
In addition, traditional Chinese medicine has received strong support from relevant national departments in recent years, and the approval criteria for innovative Chinese medicine drugs are also being continuously standardized, and the industry believes that the supply-side reform has ushered in an incremental logic, and the key track directions include innovative Chinese medicine drugs, branded Chinese medicines and Chinese medicine formula granules
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.